CN1276777C - SARS vaccine of adenovirus carrier and preparation method, application of coronavirus S gene - Google Patents

SARS vaccine of adenovirus carrier and preparation method, application of coronavirus S gene Download PDF

Info

Publication number
CN1276777C
CN1276777C CN 200410044285 CN200410044285A CN1276777C CN 1276777 C CN1276777 C CN 1276777C CN 200410044285 CN200410044285 CN 200410044285 CN 200410044285 A CN200410044285 A CN 200410044285A CN 1276777 C CN1276777 C CN 1276777C
Authority
CN
China
Prior art keywords
sars
gene
vaccine
coronavirus
adenovirus
Prior art date
Application number
CN 200410044285
Other languages
Chinese (zh)
Other versions
CN1562365A (en
Inventor
黄文林
曾益新
汪健
刘然义
黄嘉凌
黄必军
赖坤
吴立志
梁志慧
柯妙拉
吴秀菊
Original Assignee
中山大学肿瘤防治中心
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN03126634 priority Critical
Priority to CN03126634.7 priority
Application filed by 中山大学肿瘤防治中心 filed Critical 中山大学肿瘤防治中心
Priority to CN 200410044285 priority patent/CN1276777C/en
Publication of CN1562365A publication Critical patent/CN1562365A/en
Application granted granted Critical
Publication of CN1276777C publication Critical patent/CN1276777C/en

Links

Abstract

The invention pertains to biological genetic engineering field, specificly relating to SARS vaccine of adenovirus carrier and preparation method, application of related coronavirus S gene in preparation of the SARS vaccine for preventing SARS. Through a bioengineering means, the related coronary virus S gene and a defective adenovirus are recombined, which makes protective immunogen protein or polypeptide expressing in it. A genic vaccine that can arouse the mucosal immunogenicity is produced through amplifying training, purification, and preparation, which induces a immunity reaction in the respiratory mucosa, makes the organism produce the corresponding antibody, and prevents virus from infection. Compared with the traditional inactivated viral particles vaccine, the invention has a high safety; it is convenient to operate; it is not limited by the specific conditions such as intramuscular injection; and it has an extensive clinical application prospect.

Description

Adenovirus Carrier SARS Vaccines And Its Preparation Method, the application of coronavirus S gene

One, technical field

The invention belongs to the biological gene engineering field, be specifically related to adenovirus vector SARS vaccine, its preparation method and the application of announcement associated coronavirus S gene aspect preparation prevention of atypical pneumonia (SARS) vaccine.

Two, background technology

Atypical pneumonia (atypical pneumonia) is broken out in the Chinese Guangdong area since the end of last year, morbidity is anxious, and infectiousness is strong, and antibiotic therapy is invalid.At present, this disease has been transmitted to more than 30 countries and regions, WHO with the respiratory complication of it called after serious acute (severe acuterespiratory syndrome, SARS).

At present, the scientist of world many countries all from different patients serums independent separate to novel coronavirus (coronavirus), the virus gene sequence analysis result shows, they and known coronavirus have 50%~60% homology, The World Health Organization (WHO) announces that the pathogen that causes SARS is the variant of coronavirus.

Coronavirus is a kind of RNA viruses of non-segmental normal chain, and the nearly 30kb of its genome can propagate in humans and animals, the main respiratory system that infects humans and animals, the coronavirus granule is a kind ofly to have inner core and cyst membrane bag by ground virus, has four kinds of structural protein: and spike protein (spike, S), memebrane protein (membrance, M), and envelope protein (envelop, E), and nucleoprotein (nucleoprotein, N).Because coronavirus is a kind of RNA viruses, and is very unstable, undergo mutation easily to escape host's immunological surveillance and repulsion.Therefore, must search out good stability in the SARS associated coronavirus and have the antigen of immanoprotection action, with the development of the vaccine of being correlated with.

The virus particle vaccine of present less application deactivation, because whole virus particles has been carried viral full genome, safety concerns is bigger.Though coronavirus previously easily obtains at In vitro culture, this time the coronavirus toxicity that SARS is relevant greatly and genetic background imperfectly understand, so mass preparation coronavirus granule is infeasible.The exploitation that develops into subunit vaccine of technique for gene engineering provides a great convenience, and the operability of subunit vaccine and biological safety are good.Have immunogenic virus antigen determinant if can screen, in conjunction with technique for gene engineering, can transform antigenic determinant easily, to strengthen its stability, immunogenicity, biological safety.Obviously, by technique for gene engineering, can prepare effective subunit vaccine easily.

According to studies show that at present; in the known four kinds of structural protein of coronavirus; spike protein (spike S) has the structural protein of inducing protective immunological reaction; part scholar's research structure is verified, and coronavirus spike protein C-terminal is its antigen decision family place; simultaneously; the SARS associated coronavirus causes infection by respiratory tract, and the vaccine that can prevent SARS is not arranged at present yet.

In addition, data shows, adenovirus itself is easy to infect the respiratory mucosa epithelium, more easily induce the respiratory mucosa immunoreation, and adenovirus is made the immunogen of vector expression and is expressed in host cell, processes, folds, modifies, offers, basically kept immunogenic native conformation, the biological activity height.

Described condition provides solid theory for utilizing defective adenoviral as carrier development and production adenovirus SARS vaccine.

Three, summary of the invention

First purpose of the present invention is to provide a kind of adenovirus SARS vaccine that can prevent epidemic disease " atypical pneumonia ", better prevents the generation and the propagation of " atypical pneumonia "; Another object of the present invention is to provide a kind of defective adenoviral that utilizes as carrier, by means such as gene clone, reorganization, prepares the method for adenovirus vector SARS vaccine and discloses the application of SARS associated coronavirus S gene in the preparation vaccine.

The object of the present invention is achieved like this: by the biological engineering means, (coronavirus has four structural genes with SARS associated coronavirus S gene, the S gene is one of them, detailed description sees below) combine with the defective adenoviral reorganization, constitute a kind of gene vaccine that can cause mucosal immunity originality.

Used Spike gene fragment order is:

The S gene order of being announced among the use Gene bank (Gene bank query ID:, as follows according to sequential design PCR primer gbAY278554.2) as masterplate:

V1 GGTCTAGAGT?TGTGGTTTCA?AGTGAT

V2 TTTCTAGACC?ATGGGTTGTG?TCCTTGCT

V3 TTTCTAGACC?ATGGCATATA?GGTTCAATG

V4 TAGGTACCAA?TGCCAGTAGT?GGTG

V5 TTGGTACCTC?CGCCTCGACT?TT

V6 CCGGTACCAT?AAGTTCGTTT?ATGTGT

Wherein V1 and V4 are a pair of, amplification S gene N end fragment; V2 and V5 are a pair of primer, amplification S gene M district fragment; V3 and V6 are a pair of primer, amplification S gene C end fragment (as Fig. 1), and the structure after the amplification is seen Fig. 2.

The preparation of adenovirus SARS vaccine:

At first, collect to close and separate rehabilitation patient's serum, obtain the total RNA of coronavirus, by reverse transcription, step such as check order, select and obtain the S gene by separation and Extraction.Then, the S gene clone is obtained clone body (depositary institution: Chinese typical culture collection center to the pShuttle plasmid; Preservation date: on May 17th, 2003; Preserving number: CCTCC M 203036 E.coliDH5a/pShuttle-SN and CCTCC M 203037 E.coli DH5a/pShuttle-SC), again with itself and adenovirus skeleton plasmid (pAdeno-X TM) connect (wherein pShuttle, pAdeno-X be all available from CLONTECH Laboratory, Inc, USA).Connect the common rotaring redyeing 293 cell in back, after further purification is identified, increase in a large number with 293 cells, collect viral liquid, separation and purification is adenovirus SARS vaccine.It can make the medicament of spray or other form.The major technology route is seen Fig. 4.

The present invention is a kind of recombinant vaccine, promptly be to use the gene vaccine of defective adenoviral as carrier, the adenovirus that its utilization itself is easy to infect the respiratory mucosa epithelium expresses former albumen of protective immunity or polypeptide as carrier therein, induces the respiratory mucosa immunoreation; By the mucosa immunity-inducing reaction, make body produce corresponding antibodies, prevent virus infection.The present invention and traditional inactivated virus particle vaccine relatively, it is safe, and easy to use, not limited by specified conditions such as intramuscular injection.

At present, SARS propagates all over the world fast, as a kind of viral infectious, does not find the medicine that can effectively treat now as yet, and in such cases, prevention is best means.Confirmed that now SARS associated coronavirus spike protein C-terminal is its antigen decision family place.Therefore, the present invention is just according to this discovery, synthetic SARS associated coronavirus spike protein gene, it is cloned into adenovirus vector, form through amplification cultivation, purification, preparation, can effectively induce mucosa to produce antibody, produce humoral immunization and prevent the virus infection body, have potential applicability in clinical practice widely.

Four, description of drawings

Fig. 1 is a S gene fragment amplification sketch map.

Fig. 2 is the recombination deficient mutant adenovirus structure chart that has S gene (Spike-S).

Fig. 3 is pShuttle-Sc, pShuttle-S M, pShuttle-S NRecombinant enzyme action result.

Fig. 4 is pShuttle-Sc, pShuttle-S M, pShuttle-S NThe recombinant sequencing result.

Fig. 5 is that RT-PCR detects Ad-S NAnd Ad-S MThe expression result of the test

Fig. 6 is that Western blot detects Ad-S NThe expression result of the test

Fig. 7 is Ad-S NInjection or respiratory immunity all induce female rats to produce the expression in vivo result of the test of specific antibody (IgG)

Fig. 8 is Ad-S NInjection or respiratory immunity all induce male rat to produce the expression in vivo result of the test of specific antibody (IgG)

Fig. 9 is the technology path figure of vaccine production of the present invention.

Five, the specific embodiment

Below will further specify the present invention by specific embodiment.

Embodiment 1

The preparation method of adenovirus vector SARS vaccine:

Two parts that the preparation of adenovirus vector SARS vaccine is divided into that make up early stage and the later stage increases:

Make up early stage:

Obtain SARS associated coronavirus spike (S F, S N, S M, S C) behind the gene, increase with PCR method, behind PCR,, use this enzyme enzyme action pShuttle simultaneously with 37 ℃ of enzyme action of Xbal+Kpnl, connect, transformed into escherichia coli DH5a utilizes kanamycin (Kan R) the resistance screening positive colony, obtain pS behind cultivation, the purification F/ S N/ S M/ S C-Shuttle uses the l-Ceul+Pl-Scel enzyme action, uses this enzyme enzyme action PAdeno-X simultaneously TM, connecting behind the enzyme action, transformed into escherichia coli DH5a utilizes ammonia benzyl (Amp +) the resistance screening positive colony promptly gets pAd-S F/ S N/ S M/ S C

Amplification culture:

Obtain pAd-S F/ S N/ S M/ S CAfter, again through Pacl enzyme action, plasmid transfection incasing cells after linearize, incasing cells is for having integrated the cell line (strain) of C subclass 5 type adenovirus (Ad5) E1 district genes, for example 293 cells.Through plaque select, PCR is accredited as Ad-S F/ S N/ S M/ S CAfter, cultivate 293 cells in a large number, use Ad-S F/ S N/ S M/ S CInfect 293 cells, through the cesium chloride separation and purification, steps such as preparation promptly obtain adenovirus SARS vaccine.

The SARS vaccine comprises SARS associated coronavirus S gene and and defective adenoviral.Defective adenoviral is 5 type adenovirus, i.e. Ad5 of the C subclass that lacks fully of E1 district.The E3 district of this defective adenoviral can or not lack for disappearance or excalation fully.Dress CMV promoter and BGHpolyA in the defective adenoviral.

Ad-S F/S N/S M/S C

Be cloned in the adenovirus vector for SARS associated coronavirus S full length gene.

Be cloned into and comprise S for SARS associated coronavirus S gene in the adenovirus vector 1Domain is in interior sequence.

Be cloned into and comprise S for SARS associated coronavirus S gene in the adenovirus vector 2Domain is in interior sequence.

Be cloned into and comprise S for SARS associated coronavirus S gene in the adenovirus vector 1, S 2(base number is domain: 49~3585) in interior sequence.

Be cloned in the adenovirus vector 3686~3648) and the C end fragment (base number is: for SARS associated coronavirus S gene is striden the film district.

Embodiment 2

Be cloned in the adenovirus vector for SARS associated coronavirus S gene N end fragment.All the other are with embodiment 1.

Embodiment 3

Be cloned in the adenovirus vector for SARS associated coronavirus S gene intermediate segment.All the other are with embodiment 1.

Embodiment 4

Be cloned in the adenovirus vector for SARS associated coronavirus S gene C end fragment.

All the other are with embodiment 1.

Embodiment 5

S gene transformation pShuttle plasmid and evaluation:

With 37 ℃ of water bath condition enzyme action of Xbal+Kpnl, use this enzyme enzyme action pShuttle simultaneously, connect, transformed into escherichia coli DH5a cultivates, and utilizes kanamycin (Kan R) the resistance screening positive colony, obtain pShuttle-Sc, pShuttle-S respectively M, pShuttle-S N, identify and detect Sequence Identification by conventional agargel electrophoresis, the results are shown in Figure 3, Fig. 4.

Embodiment 6

The Ad-S that the clone is obtained N/ S MCarry out the vivoexpression test.

Infect the VeroE6 cell with 2.5~40MOI, discard viral suspension, add cell culture fluid, cultivate under 37 ℃, 5%CO2 condition, collect the cultured cell supernatant in infecting back 48h, detect the expression of Ad-Sn and Ad-Snm respectively with the RT-PCR method, detect the expression of Ad-Sn, the results are shown in Figure 5, Fig. 6 with Western blot method.

Embodiment 7

The Ad-S that the clone is obtained NCarry out the expression in vivo test.

Subjects is divided into groups in the following manner: Ad-Sn collunarium the group, (contrast of Ad-lacZ collunarium group, annotate anesthesia with 3% pentobarbital abdomen earlier, collunarium 0.5mL/ is only), Ad-Sn tail vein injection group, Ad-lacZ tail vein injection group (contrast, tail vein injection administration 0.5mL/ only), blank group (not doing any processing).Administration in the following manner then: be administered once continuous three weeks weekly; After the administration first time, a week get blood, last 2 week of administration the back put to death animals and get blood and tissue, measure rat anti SARS IgG concentration with the ELISA method, the results are shown in Figure 7, Fig. 8.

Embodiment 8

Green monkey kidney cell (Vero E6) cell is avoided SARS and is attacked

1. inoculation Vero E6 cell is to 96 orifice plates, 2 * 10 4/ hole.

2. after 24 hours, inoculate adenovirus SARS vaccine, method: press 4 times of virus dilution stock solutions with RPMI-1640, earlier culture fluid sucking-off in 96 orifice plates is discarded during inoculation, behind the PBS clean-out opening one time, add different dilution viral liquid, each dilution factor adds 5 holes, 50 μ L/ holes.Simultaneously with the negative contrast of RPMI-1640 (not containing virus).37 ℃, 5%CO 2, hatch 1 hour under the saturated humidity condition after, add the RPMI-1640 contain 5% new-born calf serum, 200 μ L/ holes, 37 ℃, 5%CO 2, cultivate under the saturated humidity condition.

3. after 24 hours, inoculate SARS virus, method: RPMI-1640 dilution SARS virus is to 100TCID50, earlier culture fluid sucking-off in 96 orifice plates is discarded during inoculation, behind the PBS clean-out opening one time, add different dilution viral liquid, each dilution factor adds 5 holes, 50 μ L/ holes.Simultaneously with the negative contrast of RPMI-1640 (not containing virus).37 ℃, 5%CO 2, hatch 1 hour under the saturated humidity condition after, add the RPMI-1640 contain 5% new-born calf serum, 200 μ L/ holes, 37 ℃, 5%CO 2, cultivate under the saturated humidity condition.

4. after this observed every 12 to 24 hours and record cytopathy situation, each dilution every porocyte pathological changes scoring addition draws the cytopathy index during result of calculation, gets each class mean, and is as follows:

<110〉Zhongshan Univ. Cancer Cure Center

<120〉Adenovirus Carrier SARS Vaccines And Its Preparation Method, the application of coronavirus S gene

<160>4

<210>1

<211>3780

<212>DNA

<213〉virus is planted

<220>

<221>CDS

<222>(1)…(3780)

<400>1

atgtttattt?tcttattatt?tcttactctc?actagtggta?gtgaccttga?ccggtgcacc 60

acttttgatg?atgttcaagc?tcctaattac?actcaacata?cttcatctat?gaggggggtt 120

tactatcctg?atgaaatttt?tagatcagac?actctttatt?taactcagga?tttatttctt 180

ccattttatt?ctaatgttac?agggtttcat?actattaatc?atacgtttgg?caaccctgtc 240

atacctttta?aggatggtat?ttattttgct?gccacagaga?aatcaaatgt?tgtccgtggt 300

tgggtttttg?gttctaccat?gaacaacaag?tcacagtcgg?tgattattat?taacaattct 360

actaatgttg?ttatacgagc?atgtaacttt?gaattgtgtg?acaacccttt?ctttgctgtt 420

tctaaaccca?tgggtacaca?gacacatact?atgatattcg?ataatgcatt?taattgcact 480

ttcgagtaca?tatctgatgc?cttttcgctt?gatgtttcag?aaaagtcagg?taattttaaa 540

cacttacgag?agtttgtgtt?taaaaataaa?gatgggtttc?tctatgttta?taagggctat 600

caacctatag?atgtagttcg?tgatctacct?tctggtttta?acactttgaa?acctattttt 660

aagttgcctc?ttggtattaa?cattacaaat?tttagagcca?ttcttacagc?cttttcacct 720

gctcaagaca?tttggggcac?gtcagctgca?gcctattttg?ttggctattt?aaagccaact 780

acatttatgc?tcaagtatga?tgaaaatggt?acaatcacag?atgctgttga?ttgttctcaa 840

aatccacttg?ctgaactcaa?atgctctgtt?aagagctttg?agattgacaa?aggaatttac 900

cagacctcta?atttcagggt?tgttccctca?ggagatgttg?tgagattccc?taatattaca 960

aacttgtgtc?cttttggaga?ggtttttaat?gctactaaat?tcccttctgt?ctatgcatgg 1020

gagagaaaaa?aaatttctaa?ttgtgttgct?gattactctg?tgctctacaa?ctcaacattt 1080

ttttcaacct?ttaagtgcta?tggcgtttct?gccactaagt?tgaatgatct?ttgcttctcc 1140

aatgtctatg?cagattcttt?tgtagtcaag?ggagatgatg?taagacaaat?agcgccagga 1200

caaactggtg?ttattgctga?ttataattat?aaattgccag?atgatttcat?gggttgtgtc 1260

c ttgcttgga?atactaggaa?cattgatgct?acttcaactg?gtaattataa?ttataaatat 1320

aggtatctta?gacatggc aa?gcttaggccc?tttgagagag?acatatctaa?tgtgcctttc 1380

tcccctgatg?gcaaaccttg?caccccacct?gctcttaatt?gttat tggcc?attaaatgat 1440

tatggttttt?a caccactac?tggcattggc?taccaacctt?acagagttgt?agtactttct 1500

tttgaacttt?taaatgcacc?ggccacggtt?tgtggaccaa?aattatccac?tgaccttatt 1560

aagaaccagt?gtgtcaattt?taattttaat?ggactcactg?gtactggtgt?gttaactcct 1620

tcttcaaaga?gatttcaacc?atttcaacaa?tttggccgtg?atgtttctga?tttcactgat 1680

tccgttcgag?atcctaaaac?atctgaaata?ttagacattt?caccttgcgc?ttttgggggt 1740

gtaagtgtaa?ttacacctgg?aacaaatgct?tcatctgaag?ttgctgttct?atatcaagat 1800

gttaactgca?ctgatgtttc?tacagcaatt?catgcagatc?aactcacacc?agcttggcgc 1860

atatattcta?ctggaaacaa?tgtattccag?actcaagcag?gctgtcttat?aggagctgag 1920

cat gtcgaca?cttcttatga?gtgcgacatt?cctattggag?ctggcatttg?tgctagttac 1980

catacagttt?ctttat tacg?tagtactagc?caaaaatcta?ttgtggctta?tactatgtct 2040

ttaggtgctg?atagttcaat?tgcttactct?aataacacca?ttgctatacc?tactaacttt 2100

tcaattagca?ttactacaga?agtaatgcct?gtttctatgg?ctaaaacctc?cgtagattgt 2160

aatatgtaca?tctgcggaga?ttctactgaa?tgtgctaatt?tgcttctcca?atatggtagc 2220

ttttgcacac?aactaaatcg?tgcactctca?ggtattgctg?ctgaacagga?tcgcaaca ca 2280

cgtgaagtgt?tcgctcaagt?caaacaaatg?tacaaaaccc?caactttgaa?atattttggt 2340

ggttttaatt?tttcacaaat?attacctgac?cctctaaagc?caactaagag?gtcttttatt 2400

gaggacttgc?tctttaataa?ggtgacactc?gctgatgctg?gcttc atgaa?gcaatatggc 2460

gaatgcctag?gtgatattaa?tgctag agat?ctcatttgtg?cgcagaagtt?caatggactt 2520

acagtgttgc?cacctctgct?cactgatgat?atgattgctg?cctacactgc?tgctctagtt 2580

agtggtactg?ccactgctgg?atggacattt?ggtgctggcg?ctgctcttca?aatacctttt 2640

gctatgcaaa? tggcatatag?gttcaatggc?attggagtta?cccaaaatgt?tctctatgag 2700

aaccaaaaac?aaatcgccaa?ccaatttaac?aaggcgatta?gtcaaattca?agaatcactt 2760

acaacaacat?caactgcatt?gggcaagctg?caagacgttg?ttaaccagaa?tgctcaagca 2820

ttaaacacac?ttgttaaaca?acttagctct?aattttggtg?caatttcaag?tgtgctaaat 2880

gatatcctt t?cgcgacttga?t aaagtcgag?gcggaggtac?aaattgacag?gttaattaca 2940

ggcagacttc?aaagccttca?aacctatgta?acacaacaac?taatcagggc?tgctgaaatc 3000

agggcttctg?ctaatcttgc?tgctactaaa?atgtctgagt?gtgttcttgg?acaatcaaaa 3060

agagttgact?tttgtggaaa?gggctaccac?cttatgtcct?tcccacaagc?agccccgcat 3120

ggtgttgtct?tcctacatgt?cacgtatgtg?ccatcccagg?agaggaactt?caccacagcg 3180

ccagcaattt?gtcatgaagg?caaagcatac?ttccctcgtg?aaggtgtttt?tgtgtttaat 3240

ggcacttctt?ggtttattac?acagaggaac?ttcttttctc?cacaaataat?tactacagac 3300

aatacatttg?tctcaggaaa?ttgtgatgtc?gttattggca?tcattaacaa?cacagtttat 3360

gatcctctgc?aacctgagct?tgactcattc?aaagaagagc?tggacaagta?cttcaaaaat 3420

catacatcac?cagatgttga?tcttggcgac?atttcaggca?ttaacgcttc?tgtcgtcaac 3480

attcaaaaag?aaattgaccg?cctcaatgag?gtcgctaaaa?atttaaatga?atcactcatt 3540

gaccttcaag?aattgggaaa?atatgagcaa?tatattaaat?ggccttggta?tgtttggctc 3600

ggcttcattg?ctggactaat?tgccatcgtc?atggttacaa?tcttgctttg?ttgcatgact 3660

agttgttgca?gttgcctcaa?gggt gcatgc?tcttgtggtt?cttgctgcaa?gtttgatgag 3720

gatgactctg?agccagttct?caagggtgtc?aaattacatt? acacataaac?gaacttatgg 3780

<210>2

<211>50

<212>DNA

<213〉artificial sequence

<220>

<223〉primer (a pair of) that is used for pcr amplification spike gene N end that designs according to spike gene base sequence

<400>2

ggtctagagt?tgtggtttca?agtgat

taggtaccaa?tgccagtagt?ggtg

<210>3

<211>50

<212>DNA

<213〉artificial sequence

<220>

<223〉primer (a pair of) that is used for pcr amplification spike gene M end that designs according to spike gene base sequence

<400>3

tttctagacc?atgggttgtg?tccttgct

ttggtacctc?cgcctcgact?tt

<210>4

<211>50

<212>DNA

<213〉artificial sequence

<220>

<223〉according to the primer that is used for pcr amplification spike gene M end of spike gene base sequence design (to)

<400>4

tttctagacc?atggcatata?ggttcaatg

ccggtaccat?aagttcgttt?atgtgt

Claims (18)

1, a kind of SARS vaccine is characterized in that it comprises SARS associated coronavirus S gene and replication-defective adenoviral.
2, SARS vaccine according to claim 1 is characterized in that defective adenoviral is 5 type adenoviruss of the C subclass that lacks fully of E1 district.
3, SARS vaccine according to claim 2 is characterized in that defective adenoviral is 5 type adenoviruss of the C subclass that lacks fully of E3 district.
4, SARS vaccine according to claim 2 is characterized in that defective adenoviral is 5 type adenoviruss of the C subclass of E3 district excalation.
5, SARS vaccine according to claim 2 is characterized in that defective adenoviral is 5 type adenoviruss of the C subclass that do not lack of E3 district.
6, SARS vaccine according to claim 1 and 2 is characterized in that dress CMV promoter and BGHpolyA in the defective adenoviral.
7, SARS vaccine according to claim 1 and 2 is characterized in that it comprises SARS associated coronavirus S full length gene.
8, SARS vaccine according to claim 1 and 2 is characterized in that being cloned into and comprises the sequence of S1 domain for SARS associated coronavirus S gene in the adenovirus vector.
9, SARS vaccine according to claim 1 and 2 is characterized in that being cloned into and comprises the sequence of S2 domain for SARS associated coronavirus S gene in the adenovirus vector.
10, SARS vaccine according to claim 1 and 2 is characterized in that being cloned into and comprises the sequence of S1, S2 domain for SARS associated coronavirus S gene in the adenovirus vector.
11, SARS vaccine according to claim 1 and 2, it is characterized in that being cloned in the adenovirus vector for base number be that 3686~3648 SARS associated coronavirus S gene is striden film district and C end fragment.
12, a kind of preparation method of SARS vaccine comprises
(1) obtains the S gene of SARS associated coronavirus;
(2) the S gene is combined with the defective adenoviral reorganization;
(3) transfection incasing cells;
(4) through amplification, separation, purification, make preparation.
13, SARS vaccine production method according to claim 12, it is characterized in that extracting the S gene after, it is cloned into the pshuttle plasmid, again it is connected combination with the adenovirus skeleton plasmid.
14, the preparation method of SARS vaccine according to claim 12 is characterized in that according to S gene order design PCR primer as follows:
v1 GGTCTAGAGT?TGTGGTTTCA?AGTGAT
v2 TTTCTAGACC?ATGGGTTGTG?TCCTTGCT
V3 TTTCTAGACC?ATGGCATATA?GGTTCAATG
V4 TAGGTACCAA?TGCCAGTAGT?GGTG
V5 TTGGTACCTC?CGCCTCGACT?TT
V6 CCGGTACCAT?AAGTTCGTTT?ATGTGT
15, SARS vaccine production method according to claim 12 is characterized in that incasing cells is cell line or a cell strain of having integrated C subclass 5 type adenovirus Ad5 E1 district genes.
16, SARS vaccine production method according to claim 15 is characterized in that incasing cells is 293 cells.
17, SARS vaccine production method according to claim 12 is characterized in that described preparation is spray or injection.
18, the application of SARS associated coronavirus S gene in the vaccine of preparation prevention SARS.
CN 200410044285 2003-05-21 2004-05-18 SARS vaccine of adenovirus carrier and preparation method, application of coronavirus S gene CN1276777C (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN03126634 2003-05-21
CN03126634.7 2003-05-21
CN 200410044285 CN1276777C (en) 2003-05-21 2004-05-18 SARS vaccine of adenovirus carrier and preparation method, application of coronavirus S gene

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 200410044285 CN1276777C (en) 2003-05-21 2004-05-18 SARS vaccine of adenovirus carrier and preparation method, application of coronavirus S gene

Publications (2)

Publication Number Publication Date
CN1562365A CN1562365A (en) 2005-01-12
CN1276777C true CN1276777C (en) 2006-09-27

Family

ID=34523618

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 200410044285 CN1276777C (en) 2003-05-21 2004-05-18 SARS vaccine of adenovirus carrier and preparation method, application of coronavirus S gene

Country Status (1)

Country Link
CN (1) CN1276777C (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006079290A1 (en) * 2005-01-27 2006-08-03 Institute Of Laboratory Animal Science Of Chinese Academy Of Medical Sciences A recombinant sars-cov vaccine comprising attenuated vaccinia virus carriers
CN101020055B (en) * 2006-02-16 2012-08-08 中国疾病预防控制中心性病艾滋病预防控制中心 SARS vaccine based on replicative vaccinia virus vector
WO2011093858A1 (en) * 2010-01-27 2011-08-04 Oregon Health & Science University Cytomegalovirus-based immunogenic preparations

Also Published As

Publication number Publication date
CN1562365A (en) 2005-01-12

Similar Documents

Publication Publication Date Title
Menachery et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence
CN103732749B (en) The H1N1 influenza antigens of the width reactivity of calculation optimization
Mena et al. Insect cell technology is a versatile and robust vaccine manufacturing platform
CN1211488C (en) Modified plant viruses as vectors of heterologous peptides
Guo et al. Foot-and-mouth disease virus-like particles produced by a SUMO fusion protein system in Escherichia coli induce potent protective immune responses in guinea pigs, swine and cattle
CN1090239C (en) Recombinant virus vectors
Woma et al. Phylogenetic analysis of the haemagglutinin gene of current wild-type canine distemper viruses from South Africa: lineage Africa
US8258274B2 (en) Vaccines containing canine parvovirus genetic variants
CN1056878C (en) Recombinant herpesvirus of turkeys and live vector vaccines derived thereof
CN1171637C (en) Vaccine against nepatitis B virus and human papilloma virus
US8142771B2 (en) Use of coccidian
Arnold et al. Protective vaccination against infectious bursal disease virus with whole recombinant Kluyveromyces lactis yeast expressing the viral VP2 subunit
CN1121959A (en) Recombinant infectious non-segmented negative strand RNA virus
Mikalsen et al. Characterization of a novel calicivirus causing systemic infection in Atlantic salmon (Salmo salar L.): proposal for a new genus of Caliciviridae
CN86106632A (en) acquired immune deficiency syndrome (AIDS) vaccine
JP4740133B2 (en) Composition for prevention / treatment of HBV infection and HBV-mediated disease
CN1376200A (en) DNA vaccine-PCV
Pan et al. Development of recombinant porcine parvovirus-like particles as an antigen carrier formed by the hybrid VP2 protein carrying immunoreactive epitope of porcine circovirus type 2
Ren et al. Orally delivered foot-and-mouth disease virus capsid protomer vaccine displayed on T4 bacteriophage surface: 100% protection from potency challenge in mice
CN1462309A (en) Codon-optimized papilloma virus sequences
Ilouze et al. Characterization of a novel virus causing a lethal disease in carp and koi
Moraes et al. Increased efficacy of an adenovirus-vectored foot-and-mouth disease capsid subunit vaccine expressing nonstructural protein 2B is associated with a specific T cell response
Mardani et al. Infectious bronchitis viruses with a novel genomic organization
CN87107837A (en) The polypeptide that the shell membrane gene of human immunodeficiency virus in the insect cell that is infected by the recombinant chou rhabdovirus obtains
Yuan et al. A recombinant pseudorabies virus expressing rabies virus glycoprotein: safety and immunogenicity in dogs

Legal Events

Date Code Title Description
PB01 Publication
C06 Publication
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
GR01 Patent grant
C14 Grant of patent or utility model
EE01 Entry into force of recordation of patent licensing contract

Assignee: Shenzhen City Sibiono Gene Technology Co., Ltd.

Assignor: Tumor Prevention and Therapy Center, Zhongshan Univ

Contract fulfillment period: 2007.4.25 to 2024.5.17 contract change

Contract record no.: 2008440000382

Denomination of invention: SARS vaccine of adenovirus carrier and preparation method, application of coronavirus S gene

Granted publication date: 20060927

License type: Exclusive license

Record date: 20081117

LIC Patent licence contract for exploitation submitted for record

Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2007.4.25 TO 2024.5.17; CHANGE OF CONTRACT

Name of requester: SHENZHEN CITY SAIBAINUO GENE TECHNOLOGY CO., LTD.

Effective date: 20081117

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060927

Termination date: 20170518

CF01 Termination of patent right due to non-payment of annual fee